Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft revision of the Institute’s certainty assessment… — submissions

The 15 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-001/2
Series
Public comment period
Version
1.0
Published
04 Aug 2024
Last reviewed
04 Aug 2024
Next review
04 Aug 2025
Identifier
10.71829/cei.cp.1
Certainty
Not rated
Cycle
2024 Q2
Window
02 May 2024 – 27 Jun 2024
Status
Closed
Submissions
15

§2Submissions and responses

15 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Hortensia Larsson-Ekwueme, MSc (Regulatory Affairs) Public-sector clinical trials unit
DRAFT-CERTAINTY-FR/009 received 03 May 2024

It is not clear which provisions bind the assessment committee

The respondent states that the document mixes requirements with descriptions of current practice in the same voice, so that a reader cannot tell which departures would be a breach and which would be a change of habit.

The respondent proposes that binding provisions be distinguished typographically and listed.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted15 Jul 2024

The secretariat accepts this submission. A rule indistinguishable from a description is not enforceable and does not reassure.

Binding provisions are now stated in a fixed form, are listed together in an annex, and a departure from any of them must be recorded in the document it affects with the reason, while descriptive passages are marked as descriptions of practice.

Dr Katarzyna Oppenheimer-Ade, BPharm, PhD National pharmacovigilance centre
DRAFT-CERTAINTY-FR/004 received 06 May 2024

The database set omits sources relevant to the compounds in scope

The respondent, an information specialist, states that regional databases index trials of several compounds in the Institute's scope that are not indexed in the listed sources.

The respondent proposes that the named regional databases be added to the standard set.

Declared interest. Has used a compound in the class under assessment under prescription. Declared at the Institute's request; the Institute regards a lived-experience declaration as an interest and not as a disqualification.
Secretariat responseAccepted in part11 Jul 2024

The secretariat accepts this submission in part. Two of the named sources are added to the standard set. The remainder are added as conditional sources searched where the review question concerns a compound developed or registered in the relevant region.

The standard database set is extended, the conditional sources are named together with the trigger for searching them, and every review states which sources were searched and which were not, with the reason.

Dr Bertrand Steenkamp-Ferreira, MSc (Clinical Trials) Regional hospital pharmacy department
DRAFT-CERTAINTY-FR/001 received 11 May 2024

The search date is not on the face of the document

The draft carries a publication date and a review date but not the date on which the evidence was last searched. Those are three different dates and only the third tells a reader how current the assessment is. A document published in one quarter may rest on a search run two quarters earlier, and nothing on the page allows that gap to be measured.

The respondent proposes that the search date be printed adjacent to every certainty rating rather than in the methods section, on the ground that a reader who acts on a rating is unlikely to have read the methods section first.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseAccepted30 Jul 2024

The secretariat accepts this submission. The distinction between publication, review and search dates is real and the draft did not make it visible where it mattered.

The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.

Dr Katarzyna Oppenheimer-Ade, BPharm, PhD National pharmacovigilance centre
DRAFT-CERTAINTY-FR/013 received 13 May 2024

The document should state what a reader ought to do

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

Declared interest. Has received honoraria for educational lectures from a marketing-authorisation holder of a compound named in the draft, within the preceding three years.
Secretariat responseNot accepted03 Jul 2024

The secretariat does not accept this submission, and records that the point is a reasonable one rather than a misunderstanding.

The Institute assesses evidence and does not issue recommendations, because a recommendation embeds values and a resource context that the Institute does not hold and cannot state. That constitutional limit is published on the methodology page and is not varied by consultation. The submission remains published in full.

Dr Kamila Ubertini, PharmD, BCPS Regulatory affairs, generic medicines sector
DRAFT-CERTAINTY-FR/006 received 22 May 2024

Automated assistance in screening should be disclosed and validated

The respondent asks whether any automated tool is used in screening or data extraction, and states that if one is, its performance should be reported in the same way as a human screener's agreement.

The respondent proposes that automated assistance be prohibited.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted in part17 Jul 2024

The secretariat accepts this submission in part. Disclosure and validation are adopted. A prohibition is not, because the alternative to a validated tool is not a human but a smaller search.

The methodology now requires that any automated assistance in screening or extraction be disclosed in the review, that its output be verified by a human for every included record, and that its measured performance against human screening be reported.

Dr Mordecai Glendinning-Uche, BPharm, PhD National pharmacovigilance centre
DRAFT-CERTAINTY-FR/015 received 23 May 2024

Quantitative claims are reproduced without the method that produced them

Several figures in the draft are quoted from sources that determined them by different methods. A figure obtained by one determination and a figure obtained by another are not comparable, and the draft places them in the same sentence without distinguishing them.

The respondent, an analytical chemist, proposes that every quantitative claim carry the method that produced it at the point of use rather than in the reference.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted06 Jul 2024

The secretariat accepts this submission. Placing two figures side by side is an implicit claim that they are the same kind of quantity, and in the cases identified they were not.

Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.

Dr Ivo Quintanilha, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-CERTAINTY-FR/003 received 28 May 2024

Registry records without posted results are neither screened nor counted

The respondent states that the screening procedure operates on bibliographic records and that a registered trial without a publication falls outside it entirely.

The respondent proposes that registry records be screened as records in their own right and reported as a separate category.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted31 Jul 2024

The secretariat accepts this submission. A procedure that cannot see an unreported trial cannot measure how much of the evidence base is unreported.

Registry records are now screened as records in their own right, and those meeting the eligibility criteria without a posted result are reported as unreported studies with their registered outcome measures and their completion dates.

Dr Vasilisa Immelmann, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-CERTAINTY-FR/008 received 07 Jun 2024

The document should describe how an assessment becomes a decision

The respondent, employed by a health-technology assessment body, states that the methodology stops at the certainty rating and that the step from a rating to a decision is where most disagreement actually occurs.

The respondent proposes an evidence-to-decision framework.

Declared interest. Is a trustee of a patient organisation that has received a restricted educational grant from a manufacturer in the class under assessment.
Secretariat responseNoted, no amendment15 Jul 2024

The secretariat notes this submission and records the point as correct about the field and not about this document.

No amendment arises. The Institute assesses evidence and does not make decisions, because a decision requires values and a resource context the Institute does not hold. The boundary is stated on the methodology page and the submission has prompted it to be stated at the head of the document rather than in the section on scope.

Dr Bertrand Steenkamp-Ferreira, MSc (Clinical Trials) Regional hospital pharmacy department
DRAFT-CERTAINTY-FR/012 received 08 Jun 2024

The document set should be published in translation

The respondent notes that the assessments concern compounds supplied internationally and that publishing only in English restricts access to the assessment to readers who work in it.

The respondent proposes machine translation of the document set as an interim measure, with human review of the certainty language.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseNot accepted25 Jul 2024

The secretariat does not accept this submission, and records that the underlying point is sound and that the proposed remedy is the difficulty.

A translation whose certainty language has drifted is a different assessment carrying the Institute's name, and the Institute cannot review translations it does not have the capacity to review. The documents remain in English. The submission is published in full because the access problem it identifies is real and unresolved.

Dr Anselm Ashworth-Danquah, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-CERTAINTY-FR/002 received 10 Jun 2024

The treatment of sponsor-conducted evidence is unworkable where all the evidence is sponsor-conducted

The respondent states that the draft directs assessors to consider sponsor conduct as a risk-of-bias consideration, and that for several compounds every contributing trial shares one sponsor, so the direction produces a uniform downgrade that distinguishes nothing.

The respondent proposes that sponsor concentration be reported as a property of the evidence base rather than used as a downgrade.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted in part18 Jul 2024

The secretariat accepts this submission in part. Sponsor concentration becomes a reported property of the evidence base. It continues to inform the risk-of-bias assessment where a specific feature of a trial, rather than the identity of its sponsor, supports a judgement.

Sponsor concentration is now reported with every certainty rating as the number of independent sponsors contributing evidence, and a downgrade may not be made on sponsor identity alone but must name the feature of the trial on which it rests.

Dr Oswin Yorkstone, PhD (Pharmacology) Hospital microbiology and endotoxin testing service
DRAFT-CERTAINTY-FR/005 received 12 Jun 2024

Declared interests should appear on the document rather than on a separate page

The draft links to a central conflicts register. The respondent argues that a reader assessing whether to rely on a particular document should not have to leave it to find out who assessed it and what they declared.

The respondent proposes that the interests of every named contributor to a document be printed on that document.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseNoted, no amendment04 Jul 2024

The secretariat notes this submission and records that the draft already provides for it, which the respondent could reasonably have missed because the provision sits in an appendix.

Every document carries the declared interests of its named contributors in its front matter, and the central register exists so that a reader can see a person across all documents rather than one at a time. No amendment arises; the provision has been moved from the appendix into the body of the methodology document so that it is findable.

Dr Anselm Ashworth-Danquah, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-CERTAINTY-FR/011 received 16 Jun 2024

A superseded version should remain reachable from the version that replaced it

The respondent states that the draft supersedes an earlier document and that a reader who cited the earlier version has no way to reach it from the new one, which makes it impossible to see what changed.

The respondent asks that every version carry a link both to what it supersedes and to what supersedes it.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseNoted, no amendment12 Jul 2024

The secretariat notes this submission. The corrections and versioning policy already requires bidirectional version links and every superseded document is retained at its own address.

No amendment arises. The requirement is stated in the corrections and versioning policy and the amendment log of this document links to the version it replaced. The respondent is correct that the link was absent from the draft page furnished for consultation, which was a defect of the consultation copy and not of the policy.

Dr Ludmila Castellanos-Reid, MD, FRCP Independent evidence-synthesis consultancy
DRAFT-CERTAINTY-FR/007 received 17 Jun 2024

Indirectness is defined so broadly that any evidence could be downgraded under it

The respondent states that the definition covers differences in population, intervention, comparator, outcome and setting without any threshold, so that an assessor who wishes to downgrade can always find a ground.

The respondent proposes that the assessment name the specific difference and state why it would be expected to change the effect.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted17 Jul 2024

The secretariat accepts this submission. A criterion that can always be satisfied is not a criterion.

An indirectness downgrade now requires the assessor to name the specific difference and to state the mechanism by which it would be expected to change the effect, and the statement is published with the rating so that it can be disputed.

Dr Ivo Quintanilha, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-CERTAINTY-FR/014 received 17 Jun 2024

The rating conflates absence of evidence with conflicting evidence

The framework applies a single very low certainty rating to two situations a reader will act on differently. In the first, several studies exist and disagree. In the second, no study exists at all. The same badge in both places gives the same signal for two different states of knowledge.

The respondent proposes that the rating be accompanied by a standing formulation identifying which of the two applies, identical wherever it appears so that it can be recognised at a glance.

Declared interest. Employed by a university department that has received unrestricted research funding from a manufacturer of a compound in the class under assessment. The respondent had no role in that funding.
Secretariat responseAccepted19 Jul 2024

The secretariat accepts this submission in full. The distinction is real, it is decision-relevant, and the draft did not make it.

A standing formulation has been adopted and is applied to every low and very low certainty rating in the document set. The rating scale itself is unchanged, so that Institute ratings remain readable against published assessments using the same scale.

Dr Ottoline Oppenheimer-Ade, MD, MPH Primary-care research network
DRAFT-CERTAINTY-FR/010 received 25 Jun 2024

The conditions for upgrading observational evidence are too permissive

The respondent states that the draft permits an upgrade for a large effect without requiring that confounding of the magnitude needed to produce it be shown to be implausible.

The respondent proposes that upgrading be removed from the framework entirely.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted in part17 Jul 2024

The secretariat accepts this submission in part. The conditions are tightened. Upgrading is retained, because a framework that cannot recognise a strong observational signal will misrate the cases where randomisation is not available.

An upgrade for a large effect now requires an explicit statement of the confounding structure that would be needed to produce the observed effect and a reason for regarding it as implausible, and the statement is published with the rating.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.